Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference at the revised time of 3.45 pm EDT on 6 October
29 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline announces promotion of Romuald Corbau, Ph.D. to Chief Scientific Officer
28 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based...
Freeline announces supply agreement for haemophilia B program
23 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based...
Freeline to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
10 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline files registration statement for proposed initial public offering in the United States
20 juil. 2020 02h00 HE
|
Freeline Therapeutics
LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of...
Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
13 juil. 2020 11h45 HE
|
Freeline Therapeutics
- Updated FLT180a data in the B-AMAZE study in severe Haemophilia B patients demonstrated the potential for sustained normal FIX activity levels - - Additional data were presented in 5 poster...
Freeline Closes $120 Million Series C Financing Round
30 juin 2020 02h00 HE
|
Freeline Logo
LONDON, June 30, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million...
Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
29 juin 2020 09h00 HE
|
Freeline Logo
- Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients - - Additional data will be...
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
24 juin 2020 16h05 HE
|
uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
26 mars 2020 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet...